Dudediligence.

Indivior Pharmaceuticals, Inc

INDVNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$307.0MSep ’24$299.0MDec ’24$266.0MMar ’25$302.0MJun ’25$314.0MSep ’25$358.0MDec ’25$317.0MMar ’26$343.0MJun ’26
Net income, by quarter
$22.0MSep ’24$21.0MDec ’24$47.0MMar ’25$18.0MJun ’25$42.0MSep ’25$102.0MDec ’25$89.0MMar ’26$122.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$901.0M$1.09B$1.19B$1.24B
Gross profitnone on file$749.0M$919.0M$957.0M$994.0M
Operating incomenone on file−$81.0M−$152.0M$38.0M$262.0M
Net incomenone on file−$44.0M−$126.0M$7.0M$210.0M
Operating cash flownone on file−$4.0M−$300.0M$36.0M−$27.0M
Free cash flownone on file−$9.0M−$308.0M$7.0M−$93.0M
Cash$1.10B$774.0M$316.0M$319.0M$195.0M
Debtnone on filenone on file$240.0M$333.0M$319.0M
Shares outstanding702.0M136.0M137.0M125.0M125.0M